The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer

By afschroeder • March 24, 2026

Cecchini M, Han SW, Lee S, Lee KW, Kopetz S, Mizrahi J, Hong YS, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao T, Khemka V, Wainberg ZA. The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer. Clin Cancer Res. 2026 Mar 23. doi: 10.1158/1078-0432.CCR-25-3727. Epub ahead of print. PMID: 41870279.

Tags: Hematology/Oncology, Publications

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study

Kim YJ, Merle P, Finn RS, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Pinter M, Babajanyan S, Twumasi-Ankrah P, Ghadessi[...]

Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance

Markosian C, Buckley CW, Chai-Ho W, Schiller GJ. Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance. Leuk[...]

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer

Su Y, Liu C, Lu X, Chuang HY, Li G, Shao S, Kong Y, Lee JW, Ng RH, Wong S, Robert L, Warden C, Liu[...]